Sunshine Biopharma, Inc.
SBFM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$0 | -$0 | -$0 | -$0 |
| Revenue | – | $0 | $0 | $0 |
| % Growth | – | 5.7% | -7.2% | – |
| Gross Profit | – | $0 | $0 | $0 |
| % Margin | – | 36.4% | 30.7% | 32.2% |
| EBITDA | – | -$0 | -$0 | -$0 |
| % Margin | – | -20.3% | -13% | -23.1% |
| Net Income | – | -$0 | -$0 | -$0 |
| % Margin | – | -18.8% | -13.3% | -22.5% |
| EPS Diluted | – | -7.8 | -0.44 | -0.84 |
| % Growth | – | -1,672.7% | 47.6% | – |
| Operating Cash Flow | – | -$0 | -$0 | -$0 |
| Capital Expenditures | – | -$0 | -$0 | -$0 |
| Free Cash Flow | – | -$0 | -$0 | -$0 |